Pfizer, Inc. 보도자료
Merck, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer
01월 05일 10:20
Merck, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully ...
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab
2015년 12월 23일
Merck and Pfizer today announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclo...
Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
2015년 12월 10일
Merck and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treati...
Pfizer and Allergan to Combine
2015년 11월 24일
Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today announced that their boards of directors have unanimously approved, and the companies have entered into, a d...
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
2015년 11월 19일
Pfizer Inc. announced today that PROFILE 1029, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib), met its primary objective of sign...
Merck and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
2015년 11월 19일
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal anti...
Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
2015년 11월 05일
Not intended for UK-based media Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy av...
Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
2015년 10월 08일
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal anti...
머크-화이자, 전이성 메르켈세포암 치료 위한 임상용 면역치료제 아벨루맵의 FDA 신속심사 자격획득 발표
2015년 10월 08일
머크(Merck)와 화이자(Pfizer)가 오늘 미국 식품의약국(US Food and Drug Administration, 이하 FDA)이 임상용 인간 항-PD-L1 IgG1 단클론 항체인 아벨루맵(avelumab*)을 희귀하고 공격적인 피부암의 일종인 전이성 메르켈세포암(Merkel cell ...
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
2015년 09월 29일
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avel...
Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab
2015년 09월 25일
As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the...
Merck and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015
2015년 09월 11일
Merck and Pfizer today announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and effic...
Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody
2015년 05월 14일
Merck and Pfizer today announced multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab* at the 2015 American Society of Clinic...
Pfizer, Inc.
상장여부 : 비상장
본사 소재지 : NEW YORK
업종: 건강-제약
웹사이트: http://www.pfizer.com
기업 개요:
등록된 회사소개가 없습니다.